{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:22:40Z","timestamp":1791850960620,"version":"4.3.4"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,10,24]]},"DOI":"10.7759\/cureus.11132","type":"journal-article","created":{"date-parts":[[2020,10,24]],"date-time":"2020-10-24T16:10:16Z","timestamp":1603555816000},"source":"Crossref","is-referenced-by-count":28,"title":["Cardiac Adverse Events With Remdesivir in COVID-19 Infection"],"prefix":"10.7759","author":[{"given":"Anupam K","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara M","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikash","family":"Priyadarshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.5811\/westjem.2020.5.47658","article-title":"Remdesivir for the treatment of COVID- 19: a systematic review of the literature","volume":"21","author":"Musa A","year":"2020","unstructured":"Musa A, Pendi K, Hashemi A, et al.. Remdesivir for the treatment of COVID- 19: a systematic review of the literature. West J Emerg Med. 2020, 21:737-741. 10.5811\/westjem.2020.5.47658","journal-title":"West J Emerg Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112527","article-title":"A promising antiviral candidate drug for the COVID-19 pandemic: a mini-review of remdesivir","volume":"201","author":"Liang C","year":"2020","unstructured":"Liang C, Tian L, Liu Y, et al.. A promising antiviral candidate drug for the COVID-19 pandemic: a mini-review of remdesivir. Eur J Med Chem. 2020, 201:112527. 10.1016\/j.ejmech.2020.112527","journal-title":"Eur J Med Chem"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2020-4-14","article-title":"The journey of remdesivir: from Ebola to COVID-19","volume":"9","author":"Pardo J","year":"2020","unstructured":"Pardo J, Shukla A, Chamarthi G, Gupte A. The journey of remdesivir: from Ebola to COVID-19. Drugs Context. 2020, 9:2020-4-14. 10.7573\/dic.2020-4-14","journal-title":"Drugs Context"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2398","article-title":"Review of emerging pharmacotherapy for the treatment of coronavirus disease 2019","volume":"40","author":"Barlow A","year":"2020","unstructured":"Barlow A, Landoff K, Barlow B, Yeung S. Review of emerging pharmacotherapy for the treatment of coronavirus disease 2019. Pharmacotherapy. 2020, 40:416-437. 10.1002\/phar.2398","journal-title":"Pharmacotherapy"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007016","article-title":"Compassionate use of Remdesivir for patients with severe Covid-19","volume":"382","author":"Grein J","year":"2020","unstructured":"Grein J, Ohmagari N, Shin D, et al.. Compassionate use of Remdesivir for patients with severe Covid-19. N Engl J Med. 2020, 382:2327-2336. 10.1056\/NEJMoa2007016","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/v11040326","article-title":"Mechanism of inhibition of ebola virus RNA-dependent RNA polymerase by Remdesivir","volume":"11","author":"Tchesnokov E","year":"2019","unstructured":"Tchesnokov E, Feng J, Porter D, G\u04e7tte M. Mechanism of inhibition of ebola virus RNA-dependent RNA polymerase by Remdesivir. Viruses. 2019, 11:326. 10.3390\/v11040326","journal-title":"Viruses"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00221-18","article-title":"Coronavirus susceptibility to the antiviral Remdesivir (GS-5734) Is mediated by the viral polymerase and the proofreading exoribonuclease","volume":"9","author":"Agostini M","year":"2018","unstructured":"Agostini M, Andres E, Sims A, et al.. Coronavirus susceptibility to the antiviral Remdesivir (GS-5734) Is mediated by the viral polymerase and the proofreading exoribonuclease. mBio. 2018, 9:e00221-18. 10.1128\/mBio.00221-18","journal-title":"mBio"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/CTS.12840","article-title":"Safety, tolerability, and pharmacokinetics of Remdesivir, an antiviral for treatment of COVID-19, in health subjects","volume":"13","author":"Humeniuk R","year":"2020","unstructured":"Humeniuk R, Mathias A, Cao H, et al.. Safety, tolerability, and pharmacokinetics of Remdesivir, an antiviral for treatment of COVID-19, in health subjects. Clin Transl Sci. 2020, 13:896-906. 10.1111\/CTS.12840","journal-title":"Clin Transl Sci"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.fct.2020.111639","article-title":"An overview of the safety assessment of medicines currently used in the COVID-19 disease treatment","volume":"144","author":"Javorac D","year":"2020","unstructured":"Javorac D, Grahovac L, Manic L, et al.. An overview of the safety assessment of medicines currently used in the COVID-19 disease treatment. Food Chem Toxicol. 2020, 144:111639. 10.1016\/j.fct.2020.111639","journal-title":"Food Chem Toxicol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2020.04.054","article-title":"Cardiovascular safety of potential drugs for the treatment of Coronavirus disease 2019","volume":"128","author":"Aggarwal G","year":"2020","unstructured":"Aggarwal G, Henry BM, Aggarwal S, Bangalore S. Cardiovascular safety of potential drugs for the treatment of Coronavirus disease 2019. Am J Cardiol. 2020, 128:147-150. 10.1016\/j.amjcard.2020.04.054","journal-title":"Am J Cardiol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of Covid-19- preliminary report","author":"Beigel JH","year":"2020","unstructured":"Beigel JH, Tomashek KM, Dodd LE, et al.. Remdesivir for the treatment of Covid-19- preliminary report. N Engl J Med. 2020, 10.1056\/NEJMoa2007764","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1177\/1708538120941635","article-title":"Antimalarial and cytotoxic drugs on COVID-19 and the cardiovascular burden: literature review and lessons to be learned","volume":"1708538120941635","author":"Sultan S","year":"2020","unstructured":"Sultan S, Acharya Y. Antimalarial and cytotoxic drugs on COVID-19 and the cardiovascular burden: literature review and lessons to be learned. Vascular. 2020, 1708538120941635:10.1177\/1708538120941635","journal-title":"Vascular"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910993","article-title":"A randomized, controlled trial of ebola virus disease therapeutics","volume":"381","author":"Mulangu S","year":"2019","unstructured":"Mulangu S, Dodd L, Davey R, et al.. A randomized, controlled trial of ebola virus disease therapeutics. N Eng J Med. 2019, 381:2293-2303. 10.1056\/NEJMoa1910993","journal-title":"N Eng J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.5582\/ddt.2020.01015","article-title":"Rapid review for the anti-coronavirus effect of remdesivir","volume":"14","author":"Li Z","year":"2020","unstructured":"Li Z, Wang X, Cao D, Sun R, Li C, Li G. Rapid review for the anti-coronavirus effect of remdesivir. Drug Discov Ther. 2020, 14:73-76. 10.5582\/ddt.2020.01015","journal-title":"Drug Discov Ther"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1097\/CRD.0000000000000337","article-title":"A review of Remdesivir for COVID- 19: data to date","volume":"28","author":"Mehta M","year":"2020","unstructured":"Mehta M, Shyh G. A review of Remdesivir for COVID- 19: data to date. Cardiol Rev. 2020, 28:332-334. 10.1097\/CRD.0000000000000337","journal-title":"Cardiol Rev"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/44072-cardiac-adverse-events-with-remdesivir-in-covid-19-infection","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:22:28Z","timestamp":1707506548000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/44072-cardiac-adverse-events-with-remdesivir-in-covid-19-infection"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,24]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.11132","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10,24]]}}}